Advanced Cell Technology, Inc. (ACTC)

http://www.advancedcell.com

Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662
info@advancedcell.com

Massachusetts Laboratory Facility:

381 Plantation Street
Biotech V
Worcester, MA 01605
Tel: (508) 756-1212
Fax: (508) 756-4468

Advanced Cell Technology, Inc. (OTCBB:ACTC - News) is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside.

The Company is in the final stages of moving toward the initiation of Phase I clinical trials for its Retinal Pigment Epithelial (RPE) program which addresses a number of retinal degenerative disorders. ACT has published positive data from animal studies for the RPE cell program - completed in collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU) - as well as recently announced promising results - also in collaboration with OHSU- from GLP Safety Studies and long-term efficacy studies for the RPE therapy. Currently ACT is finalizing preclinical studies for the bio-distribution of RPE and expects spiking studies to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of the year. Advanced Cell also has moved forward rapidly with it Hemangioblast (HG) platform. ACT has published positive data in the journal NATURE Methods for its HG cellular program for the treatment of blood and cardiovascular diseases. Additionally the company's Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials.

In recent years ACT has announced the successful development of a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occasions the successful creation of human embryonic stem cell lines without the destruction or disruption of the developmental potential of the embryos. In support of its research and applications Advanced Cell owns or licenses over 380 patents and patent applications.

Management: 

Senior Executive Officers:  http://www.advancedcell.com/senior-executive-officers/

Board of Directors:  http://www.advancedcell.com/board-of-directors/

Ethics Advisory Board:  http://www.advancedcell.com/ethics-advisory-board/